One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose - 21/12/19
Abstract |
Study objective |
Despite the increased availability of naloxone, death rates from opioid overdose continue to increase. The goal of this study is to determine the 1-year mortality of patients who were treated for a nonfatal opioid overdose in Massachusetts emergency departments (EDs).
Methods |
This was a retrospective observational study of patients from 3 linked statewide Massachusetts data sets: a master demographics list, an acute care hospital case-mix database, and death records. Patients discharged from the ED with a final diagnosis of opioid overdose were included. The primary outcome measure was death from any cause within 1 year of overdose treatment.
Results |
During the study period, 17,241 patients were treated for opioid overdose. Of the 11,557 patients who met study criteria, 635 (5.5%) died within 1 year, 130 (1.1%) died within 1 month, and 29 (0.25%) died within 2 days. Of the 635 deaths at 1 year, 130 (20.5%) occurred within 1 month and 29 (4.6%) occurred within 2 days.
Conclusion |
The short-term and 1-year mortality of patients treated in the ED for nonfatal opioid overdose is high. The first month, and particularly the first 2 days after overdose, is the highest-risk period. Patients who survive opioid overdose should be considered high risk and receive interventions such as being offered buprenorphine, counseling, and referral to treatment before ED discharge.
Le texte complet de cet article est disponible en PDF.Plan
Please see page 14 for the Editor’s Capsule Summary of this article. |
|
Supervising editor: Richard C. Dart, MD, PhD. Specific detailed information about possible conflict of interest for individual editors is available at editors. |
|
Author contributions: All authors were responsible for the design of the study. OB and DB were responsible for analyzing the data. SGW wrote the article. All authors contributed to the interpretation of the results and provided intellectual contribution to the article and critically reviewed the article. All authors have read and approved the final article and take final responsibility for the decision to submit for publication in the present form. SGW takes responsibility for the paper as a whole. |
|
All authors attest to meeting the four ICMJE.org authorship criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. |
|
Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Dr. Weiner is supported by NIH grant 1-R01-DA044167. He completed an unrelated research project in 2016 funded by Kaleo Pharma, a company that produces a naloxone autoinjector, and is a former scientific advisory board member of Epidemic Solutions, LLC and General Emergency Medical Supplies Corp, both start-up companies aiming to increase availability of naloxone for bystanders. |
|
A podcast for this article is available at www.annemergmed.com. |
Vol 75 - N° 1
P. 13-17 - janvier 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?